News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Rights issue in PledPharma oversubscribed

May 13, 2014

PledPharma AB
Company Announcement

Rights issue in PledPharma oversubscribed

Stockholm, 2014-05-13 14:16 CEST (GLOBE NEWSWIRE) -- 
PledPharmas rights issue with subscription period from 25 April – 9 May 2014
was oversubscribed by 82 percent. PledPharma receives approximately SEK 20,25
million before issue costs. 

The rights issue was subscribed to approximately 98,6 percent with preferential
rights and the remaining 1,4 percent were subscribed for without preferential
rights. The new share issue was, thus, fully subscribed. Shares subscribed for
without preferential rights, will be allocated to shareholders who exercised
subscription rights in relation to the number of existing subscription rights
used by each shareholder. 

“The oversubscription confirms a great interest in PledPharma and our ongoing
clinical trial with PledOx®. The rights issue is conducted to include more
patients in the ongoing colorectal cancer study. The study investigates whether
pre-treatment with PledPharma’s drug PledOx can reduce severe chemotherapy
induced side-effects, says CEO Jacques Näsström. 

The rights issue will increase the number of shares by 1.687.314 to a total of
23 622 403 shares and the share capital will increase by SEK 88.806 to SEK
1.243 284. 

Sales notes for shares subscribed for without preferential rights will be sent
out today to affected shareholders. After registration of the share capital
increase at the Companies Registration Office, the paid interim shares in the
rights issue will be converted into new shares. Trading in the new shares is
expected to commence on NASDAQ OMX First North when the new shares are
registered in the subscriber's securities account. 

For further information please contact:

Jacques Näsström, CEO PledPharma, phone +46 73 713 09 79

Michaela Gertz, CFO PledPharma, phone +46 70 926 17 75

About PledPharma
PledPharma is a Swedish pharmaceutical company that develops new therapies for
the treatment of life threatening diseases. The initial objective is to develop
a drug, PledOx®, which reduces severe side-effects associated with
chemotherapy. The current market for supportive cancer care is some USD 10
billion. PledPharma also evaluates an existing medicines possibility to reduce
the damage that occurs on the heart muscle when patients suffer from acute
myocardial infarction. In addition to these projects, the company is also
evaluating opportunities of using our technology platform in additional areas
where there is a significant unmet medical need. PledPharma has the potential
to offer patients valuable and unique treatments for serious life-threatening
diseases where there is an opportunity fast registration in the US through
"breakthrough therapy" designation. This means that the company has the
potential to offer shareholders a good return on their investment. PledPharma
(STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is
the Certified Adviser. For further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10